PMID- 37495223
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231108
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Print)
IS  - 1479-1641 (Linking)
VI  - 20
IP  - 4
DP  - 2023 Jul-Aug
TI  - Management of diabetic neuropathy with memantine: A randomized clinical trial.
PG  - 14791641231191093
LID - 10.1177/14791641231191093 [doi]
LID - 14791641231191093
AB  - BACKGROUND: Diabetes patients frequently experience diabetic neuropathy (DN), a 
      microvascular complication that significantly reduces patients' quality of life. 
      Memantine has demonstrated potential benefits for neuropathic pains in 
      preclinical studies. This study aimed to assess the efficacy of memantine in the 
      management of peripheral neuropathy in patients with type 2 diabetes mellitus 
      (T2DM). METHOD: This randomized clinical trial includes 143 diabetic patients 
      (aged between 18 and 75 years) with a confirmed diagnosis of diabetic neuropathy. 
      Patients were randomly assigned to receive memantine 5 mg twice daily for 1 week, 
      followed by 10 mg twice daily plus gabapentin 300 mg daily (n = 72) or just 
      gabapentin 300 mg daily (n = 71) for 8 weeks. The DN4 questionnaire, 
      monofilament, tuning fork, and Tip-therm tests were used to measure neuropathy at 
      baseline and after the 8-week intervention. RESULTS: The mean score of the DN4 
      questionnaire in the memantine group was significantly lower than the control 
      group (p. value: .001). The number of patients with diabetic neuropathy 
      remarkably decreased in the memantine group at the end of the study based on the 
      performed tests (p. value: .001). CONCLUSION: Memantine functions as a beneficial 
      agent in the management of diabetic neuropathy, which would significantly improve 
      the quality of life in diabetic patients.
FAU - Jafarzadeh, Elnaz
AU  - Jafarzadeh E
AD  - Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Beheshtirouy, Samineh
AU  - Beheshtirouy S
AD  - Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Aghamohammadzadeh, Nasser
AU  - Aghamohammadzadeh N
AD  - Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Ghaffary, Saba
AU  - Ghaffary S
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Sarbakhsh, Parvin
AU  - Sarbakhsh P
AD  - Road Traffic Injury Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Shaseb, Elnaz
AU  - Shaseb E
AUID- ORCID: 0000-0001-7931-4632
AD  - Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research
JID - 101234011
RN  - 6CW7F3G59X (Gabapentin)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Humans
MH  - Adolescent
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - *Diabetic Neuropathies/diagnosis/drug therapy
MH  - Gabapentin
MH  - Memantine/adverse effects
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - Quality of Life
PMC - PMC10387673
OTO - NOTNLM
OT  - Douleur Neuropathique 4 questionnaire
OT  - Memantine
OT  - diabetes mellitus
OT  - diabetic neuropathy
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/07/27 01:09
MHDA- 2023/07/27 01:10
PMCR- 2023/07/26
CRDT- 2023/07/26 20:12
PHST- 2023/07/27 01:10 [medline]
PHST- 2023/07/27 01:09 [pubmed]
PHST- 2023/07/26 20:12 [entrez]
PHST- 2023/07/26 00:00 [pmc-release]
AID - 10.1177_14791641231191093 [pii]
AID - 10.1177/14791641231191093 [doi]
PST - ppublish
SO  - Diab Vasc Dis Res. 2023 Jul-Aug;20(4):14791641231191093. doi: 
      10.1177/14791641231191093.